(Q84558513)
Statements
[Recommendations for the use of palivizumab in the prevention of respiratory syncytial virus infection in late preterm infants (32(1) to 35(0) weeks of gestation)] (English)
X Carbonell Estrany
J Figueras Aloy
Comité de Estándares de la Sociedad Española de Neonatología